Given these data, it will be interesting to examine whether Treg are also preventing cDC2 function in contexts other than melanoma, and whether depletion of the Treg may augment the anti-tumor immune response in human tumors via increased cDC2 and CD4+ T cell activity. This evidence concerns the gene CD4 and neoplasm.